Here are five quick facts:
1. AmSurg’s target price could deviate by a maximum of $7.7 from the forecast price.
2. Analysts predict the target price could reach a high of $95 and a low of $70.
3. Zacks analysts gave the company a “strong buy” rating for the short term.
4. In the last three-month period, AmSurg shares have dropped nearly 4.8 percent.
5. The shares posted positive gains of 2.51 percent in the last four weeks.
More articles on surgery centers:
Medical Facilities reports Q3 results — 5 highlights
Clarus Eye Centre in Washington expands to new facility: 5 key notes
NC surgery center asks to transfer operating rooms: 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
